SCHEMBL4472784

SCHEMBL4472784

O=S(=O)(NCc1ccccc1)c1ccc2c(O)cccc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.62
KEAP1 Q14145 1/20 0.54
LMNA P02545 1/20 0.53
SLC12A2 P55011 1/20 0.53
SLC12A5 Q9H2X9 1/20 0.53
PKM P14618 3/20 0.53
HDAC2 Q92769 1/20 0.52
HDAC8 Q9BY41 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
HTT P42858 1/20 0.52
CA12 O43570 2/20 0.51
CA9 Q16790 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
ATM Q13315 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
POLB P06746 4/20 0.51
VCAM1 P19320 1/20 0.51
IDO1 P14902 1/20 0.51
ALDH1A1 P00352 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4478227 0.87 CYP19A1 (0.61) CYP19A1CA12CA9CYP1A2CYP3A4
SCHEMBL4489568 0.87 AKR1C3 (0.57) LMNAHDAC2HDAC8HDAC6POLB
SCHEMBL4476668 0.85 CYP19A1 (0.60) CYP19A1LMNAHTTPOLBALDH1A1
SCHEMBL4472758 0.85 HDAC3 (0.54) CYP19A1LMNAHDAC8HDAC6HTT
SCHEMBL4480958 0.84 CYP19A1 (0.66) CYP19A1CYP1A2CYP3A4L3MBTL1POLB
SCHEMBL4478162 0.84 CA2 (0.56) CYP19A1CA12CA9CYP1A2CYP3A4
SCHEMBL4470901 0.84 CYP19A1 (0.62) CYP19A1KEAP1LMNASLC12A2SLC12A5
SCHEMBL4482549 0.81 L3MBTL1 (0.58) LMNAPKMATML3MBTL1POLB
SCHEMBL3681880 0.81 CYP19A1 (0.85) CYP19A1KEAP1LMNASLC12A2SLC12A5
SCHEMBL38660104 0.81 CYP19A1 (0.85) CYP19A1KEAP1LMNASLC12A2SLC12A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 US claimed
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 US disclosed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215645-A1 Amide derivatives OGG1, HDAC1, BCL2A1 CYP19A1 552/4885KEAP1 551/4885LMNA 941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.